SSSue Simpson

Sue Simpson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sue Simpson has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Health Care Needs Assessment, First Series, Volume 2, Second Edition

    by Andrew Stevens, James Raftery, Jonathan Mant, Sue Simpson

    Health care needs assessment provides information to plan, negotiate and change services for the better, and to improve health in other ways. The first edition of this series established itself as a key source on health care needs for specific conditions supported by the Department of Health. Now in its second edition it provides vital updates taking into account how health care has moved on and how the structure of the UK's health service has changed. Each of the chapters follows the same structure; each analysing its topic, reviewing the incidence and prevalence, the range of services available, and the effectiveness of those services. It describes the central role and aim of health care needs assessment in the NHS health care reforms and explains the 'epidemiological approach' to needs assessment and its effectiveness. Volume 1 includes diabetes mellitus, renal disease, stroke, lower respiratory disease, coronary heart disease, colorectal cancer, cancer of the lung, osteoarthritis affecting the hip and knee, cataract surgery and groin hernia. Volume 2 includes varicose veins and venous ulcers, benign prostatic hyperplasia, severe mental illness, Alzheimer's disease, alcohol misuse, drug misuse, learning disabilities, community child health services and contraception, induced abortion and fertility services. All health professionals, including policy makers and shapers and those assessing quality of service will find this book an essential resource. Health care needs assessment provides information to plan, negotiate and change services for the better, and to improve health in other ways. The first edition of this series established itself as a key source on health care needs for specific conditions supported by the Department of Health. Now in its second edition it provides vital updates taking into account how health care has moved on and how the structure of the UK's health service has changed. Each of the chapters follows the same structure; each analysing its topic, reviewing the incidence and prevalence, the range of services available, and the effectiveness of those services. It describes the central role and aim of health care needs assessment in the NHS health care reforms and explains the 'epidemiological approach' to needs assessment and its effectiveness. Volume 1 includes diabetes mellitus, renal disease, stroke, lower respiratory disease, coronary heart disease, colorectal cancer, cancer of the lung, osteoarthritis affecting the hip and knee, cataract surgery and groin hernia. Volume 2 includes varicose veins and venous ulcers, benign prostatic hyperplasia, severe mental illness, Alzheimer's disease, alcohol misuse, drug misuse, learning disabilities, community child health services and contraception, induced abortion and fertility services. All health professionals, including policy makers and shapers and those assessing quality of service will find this book an essential resource. Health care needs assessment provides information to plan, negotiate and change services for the better, and to improve health in other ways. The first edition of this series established itself as a key source on health care needs for specific conditions supported by the Department of Health. Now in its second edition it provides vital updates taking into account how health care has moved on and how the structure of the UK's health service has changed. Each of the chapters follows the same structure; each analysing its topic, reviewing the incidence and prevalence, the range of services available, and the effectiveness of those services. It describes the central role and aim of health care needs assessment in the NHS health care reforms and explains the 'epidemiological approach' to needs assessment and its effectiveness. Volume 1 includes diabetes mellitus, renal disease, stroke, lower respiratory disease, coronary heart disease, colorectal cancer, cancer of the lung, osteoarthritis affecting the hip and knee, cataract surgery and groin hernia. Volume 2 includes varicose veins and venous ulcers, benign prostatic hyperplasia, severe mental illness, Alzheimer's disease, alcohol misuse, drug misuse, learning disabilities, community child health services and contraception, induced abortion and fertility services. All health professionals, including policy makers and shapers and those assessing quality of service will find this book an essential resource. Health care needs assessment provides information to plan, negotiate and change services for the better, and to improve health in other ways. The first edition of this series established itself as a key source on health care needs for specific conditions supported by the Department of Health. Now in its second edition it provides vital updates taking into account how health care has moved on and how the structure of the UK's health service has changed. Each of the chapters follows the same structure; each analysing its topic, reviewing the incidence and prevalence, the range of services available, and the effectiveness of those services. It describes the central role and aim of health care needs assessment in the NHS health care reforms and explains the 'epidemiological approach' to needs assessment and its effectiveness. Volume 1 includes diabetes mellitus, renal disease, stroke, lower respiratory disease, coronary heart disease, colorectal cancer, cancer of the lung, osteoarthritis affecting the hip and knee, cataract surgery and groin hernia. Volume 2 includes varicose veins and venous ulcers, benign prostatic hyperplasia, severe mental illness, Alzheimer's disease, alcohol misuse, drug misuse, learning disabilities, community child health services and contraception, induced abortion and fertility services. All health professionals, including policy makers and shapers and those assessing quality of service will find this book an essential resource. Health care needs assessment provides information to plan, negotiate and change services...


  • Open Access

    PATIENT AND PUBLIC INVOLVEMENT IN EARLY AWARENESS AND ALERT ACTIVITIES: AN EXAMPLE FROM THE UNITED KINGDOM

    by Sue Simpson, Alison Cook, Kathryn Miles

    Objectives: The aim of this study is to report on the experiences, benefits, and challenges of patient and public involvement and engagement (PPIE) from a publicly funded early awareness and alert (EAA) system in the United Kingdom. Methods: Using email, telephone, a Web site portal, Twitter and focus groups, patients and the public were involved and engaged in the recognized stages of an EAA system: identification, filtration, prioritization, early assessment, and dissemination. Results: Approaches for PPIE were successfully integrated into all aspects of the National Institute for Health Research Horizon Scanning Research and Intelligence Centre's EAA system. Input into identification activities was not as beneficial as involvement in prioritization and early assessment. Patients gave useful insight into the Centre's Web site and engaging patients using Twitter has enabled the Centre to disseminate outputs to a wider audience. Conclusions: EAA systems should consider involving and engaging with patients and the public in identification, prioritization, and assessment of emerging health technologies where practicable. Further research is required to examine the value and impact of PPIE in EAA activities and in the early development of health technologies.


  • Open Access

    OP06 Past Speculations Of Future Health Technologies: What Did They Predict?

    by Lucy Doos, Claire Packer, Derek Ward, Sue Simpson, Andrew Stevens

    INTRODUCTION: Rapid technological innovation is leading to new health technologies and interventions becoming available to healthcare markets at increasing speed; these often cost more than current alternatives and significantly affect the cost of healthcare services and delivery (1). Identifying future technologies supports service preparedness, long-term planning, and strategic decision making. The aim of this study was to describe and classify health technologies predicted in fifteen forecasting studies according to their type, purpose and clinical use, and relate these to the original purpose and timing of the forecasting studies. METHODS: This was a descriptive study of predicted healthcare technologies identified in fifteen forecasting studies included in a previously published systematic review (2). Outcomes related to (i) each forecast study including country, year, intent and forecasting methods used, and (ii) the predicted technology type, purpose, targeted clinical area and forecast timeframe. RESULTS: We identified 896 predicted health-related topics, of which 685 were health technologies. Of these, 19.1 percent were diagnostic or imaging tests and 14.3 percent devices or biomaterials; 38.1 percent were intended to treat or manage disease and 21.6 percent to diagnose or monitor disease. The most frequent targeted clinical areas were infectious diseases followed by cancer, circulatory and nervous system disorders. The mean timeframe for technology forecast was 11.6 years (Standard Deviation, SD = 6.6). The forecasting timeframe significantly differed by technology type (p = .002), the intent of the forecasting group (p < .0001), and the methods used (p < .0001). CONCLUSIONS: Our description and classification of predicted health-related technologies from prior forecasting studies provides an overview of the technological and clinical frontiers of innovation in health and healthcare provision.

  • Open Access

    Past speculations of the future: a review of the methods used for forecasting emerging health technologies

    by Lucy Doos, Claire Packer, Derek Ward, Sue Simpson, Andrew Stevens

    Objectives Forecasting can support rational decision-making around the introduction and use of emerging health technologies and prevent investment in technologies that have limited long-term potential. However, forecasting methods need to be credible. We performed a systematic search to identify the methods used in forecasting studies to predict future health technologies within a 3–20-year timeframe. Identification and retrospective assessment of such methods potentially offer a route to more reliable prediction. Design Systematic search of the literature to identify studies reported on methods of forecasting in healthcare. Participants People are not needed in this study. Data sources The authors searched MEDLINE, EMBASE, PsychINFO and grey literature sources, and included articles published in English that reported their methods and a list of identified technologies. Main outcome measure Studies reporting methods used to predict future health technologies within a 3–20-year timeframe with an identified list of individual healthcare technologies. Commercially sponsored reviews, long-term futurology studies (with over 20-year timeframes) and speculative editorials were excluded. Results 15 studies met our inclusion criteria. Our results showed that the majority of studies (13/15) consulted experts either alone or in combination with other methods such as literature searching. Only 2 studies used more complex forecasting tools such as scenario building. Conclusions The methodological fundamentals of formal 3–20-year prediction are consistent but vary in details. Further research needs to be conducted to ascertain if the predictions made were accurate and whether accuracy varies by the methods used or by the types of technologies identified.


  • Open Access

    New and emerging technologies for the treatment of inherited retinal diseases: a horizon scanning review

    by J Smith, D Ward, M Michaelides, A T Moore, S Simpson

    The horizon scanning review aimed to identify new and emerging technologies in development that have the potential to slow or stop disease progression and/or reverse sight loss in people with inherited retinal diseases (IRDs). Potential treatments were identified using recognized horizon scanning methods. These included a combination of online searches using predetermined search terms, suggestions from clinical experts and patient and carer focus groups, and contact with commercial developers. Twenty-nine relevant technologies were identified. These included 9 gene therapeutic approaches, 10 medical devices, 5 pharmacological agents, and 5 regenerative and cell therapies. A further 11 technologies were identified in very early phases of development (typically phase I or pre-clinical) and were included in the final report to give a complete picture of developments ‘on the horizon’. Clinical experts and patient and carer focus groups provided helpful information and insights, such as the availability of specialised services for patients, the potential impacts of individual technologies on people with IRDs and their families, and helped to identify additional relevant technologies. This engagement ensured that important areas of innovation were not missed. Most of the health technologies identified are still at an early stage of development and it is difficult to estimate when treatments might be available. Further, well designed trials that generate data on efficacy, applicability, acceptability, and costs of the technologies, as well as the long-term impacts for various conditions are required before these can be considered for adoption into routine clinical practice.


  • Open Access

    EUROSCAN INTERNATIONAL NETWORK MEMBER AGENCIES: THEIR STRUCTURE, PROCESSES, AND OUTPUTS

    by Claire Packer, Sue Simpson, Rosimary Terezinha de Almeida

    Objectives: The EuroScan International Network is a global network of publicly funded early awareness and alert (EAA) systems for health technologies. We describe the EuroScan member agency systems and methods, and highlight the potential for increased collaboration.Methods: EuroScan members completed postal questionnaires supplemented with telephone interviews in 2012 to elicit additional information and check equivalence of responses. Information was updated between March and May 2013.Results: Fifteen of the seventeen member agencies responded. The principal purpose of agencies is to inform decisions on coverage or reimbursement of health services and decisions on undertaking secondary research. The main users of information are national governments; health professionals; health services purchasers, commissioners, and decision makers; and healthcare providers. Most EuroScan agencies are small with almost half having fewer than two whole time equivalent staff. Ten agencies use both active and passive identification approaches, four use only active approaches. Most start identification in the experimental or investigational stages of the technology life cycle. All agencies assessed technologies when they are between the investigational and established, but under diffusion stages. Barriers to collaboration revolve around different system aims, purposes, and requirements; a lack of staff, finance, or opportunity; language differences; and restrictions on dissemination.Conclusions: Although many barriers to collaboration were identified, the majority of agencies were supportive of increased collaboration either involving the whole EuroScan Network or between individual agencies. Despite differences in the detailed identification processes, members thought that this was the most feasible phase to develop additional collaboration.


  • Open Access

    Regenerative Medicine Techniques in Cardiovascular Disease: Where is the Horizon?

    by Claire Packer, Beth Boddice, Sue Simpson

    Regenerative medicine techniques to restore cardiac and vascular function are being increasingly investigated as management options for cardiovascular disease. The authors set out to identify emerging regenerative techniques in cardiovascular disease and investigate their stage of development. The relevant networks in the field in the UK were contacted and online sources for cell therapy, tissue engineering, and other regenerative techniques and products were searched for online. A total of 49 Phase II, II/III and III trials of regenerative products or techniques were identified: 13 Phase III, eight Phase II/III and 28 Phase II trials. Twelve of the Phase III trials are for myocardial ischemia and involve an intracoronary infusion or intramyocardial injection of autologous bone marrow-derived stem cells. Most of those in Phase III trials are, however, associated either with an unproven delivery technique or cellular approach. The authors conclude that translation into clinical practice and diffusion into health systems is some way off.


  • Burden of disease, research funding and innovation in the UK: Do new health technologies reflect research inputs and need?

    by Derek Ward, Orsolina Martino, Claire Packer, Sue Simpson, Andrew Stevens

    Objectives: New and emerging health technologies (innovation outputs) do not always reflect conditions representing the greatest disease burden. We examine the role of research and development (R&D) funding in this relationship, considering whether areas with fewer innovative outputs receive an appropriate share of funding relative to their disease burden. Methods: We report a retrospective observational study, comparing burden of disease with R&D funding and innovation output. UK disability-adjusted life years (DALYs) and deaths came from the World Health Organization (WHO) 2004 Global Burden of Disease estimates; funding estimates from the UK Clinical Research Collaboration’s 2006 Health Research Analysis; and innovation output was estimated by the number of new and emerging technologies reported by the National Institute for Health Research (NIHR) Horizon Scanning Centre between 2000 and 2009. Results: Disease areas representing the biggest burden were generally associated with the most funding and innovation output; cancer, neuropsychiatric conditions and cardiovascular disease together comprised approximately two-thirds of DALYs, funding and reported technologies. Compared with DALYs, funding and technologies were disproportionately high for cancer, and technologies alone were disproportionately high for musculoskeletal conditions and endocrine/metabolic diseases. Neuropsychiatric conditions had comparatively few technologies compared to both DALYs and funding. The relationship between DALYs and innovation output appeared to be mediated by R&D funding. Conclusions: The relationship between burden of disease and new and emerging health technologies for different disease areas is partly dependent on the associated level of R&D funding (input). Discrepancies among key groups may reflect differential focus of research funding across disease areas.


  • Open Access

    Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UK

    by Derek J Ward, Orsolina I Martino, Sue Simpson, Andrew J Stevens

    Objective To describe trends in new drugs launched in the UK from 1982 to 2011 and test the hypothesis that the rate of new drug introductions has declined over the study period. There is wide concern that pharmaceutical innovation is declining. Reported trends suggest that fewer new drugs have been launched over recent decades, despite increasing investment into research and development. Design Retrospective observational study. Setting and data source Database of new preparations added annually to the British National Formulary (BNF). Main outcome measures The number of new drugs entered each year, including new chemical entities(NCEs) and new biological drugs, based on first appearance in the BNF. Results There was no significant linear trend in the number of new drugs introduced into the UK from 1982 to 2011. Following a dip in the mid-1980s (11–12 NCEs/new biologics introduced annually from 1985 to 1987), there was a variable increase in the numbers of new drugs introduced annually to a peak of 34 in 1997. This peak was followed by a decline to approximately 20 new drugs/year between 2003 and 2006, and another peak in 2010. Extending the timeline further back with existing published data shows an overall slight increase in new drug introductions of 0.16/year over the entire 1971 to 2011 period. Conclusions The purported ‘innovation dip’ is an artefact of the time periods previously studied. Reports of declining innovation need to be considered in the context of their timescale and perspective.


  • Open Access

    The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss

    by Luan Linden Phillips, Maria Bitner-Glindzicz, Nicholas Lench, Karen P. Steel, Cordelia Langford, Sally J. Dawson, Adrian Davis, Sue Simpson, Claire Packer

    Objective: To explore the future potential of genetic screening to detect newborns at risk of childhood-onset hearing loss. Design: An expert led discussion of current and future developments in genetic technology and the knowledge base of genetic hearing loss to determine the viability of genetic screening and the implications for screening policy. Results and Discussion: Despite increasing pressure to adopt genetic technologies, a major barrier for genetic screening in hearing loss is the uncertain clinical significance of the identified mutations and their interactions. Only when a reliable estimate of the future risk of hearing loss can be made at a reasonable cost, will genetic screening become viable. Given the speed of technological advancement this may be within the next 10 years. Decision-makers should start to consider how genetic screening could augment current screening programmes as well as the associated data processing and storage requirements. Conclusion: In the interim, we suggest that decision makers consider the benefits of (1) genetically testing all newborns and children with hearing loss, to determine aetiology and to increase knowledge of the genetic causes of hearing loss, and (2) consider screening pregnant women for the m.1555A> G mutation to reduce the risk of aminoglycoside antibiotic-associated hearing loss.